Biotech RadarJobs updated

COMPANY

NS Pharma, Inc.

HQ: Paramus, NJ source · nspharma.com ↗ · Mid-Atlantic

Status: Acquired, now part of Nippon Shinyaku · How status works

Clinical Phase 3

8 open jobs · last seen Oct 23, 2026 · 14 sources

Keywords: cell therapy small molecule rare diseases Duchenne Muscular Dystrophy DMD Primary Myelofibrosis Post-essential Thrombocythemia Myelofibrosis Post-polycythemia Vera Myelofibrosis Exon 44 Eosinophilic Granulomatosis With Polyangiitis Churg-Strauss Syndrome Pulmonary Arterial Hypertension Pulmonary Hypertension Associated With Interstitial Lung Disease Liver Neoplasms Neoplasm Metastasis Local Neoplasm Recurrences Viltolarsen NS-018 NS-065/NCNP-01 NS-089/NCNP-02 NS-229 NS-9 [Poly I: Poly C]

Profile checked Oct 10, 2026

8Open jobs15Trials (company is sponsor)

Hiring

TitleLocation (from posting)Employer postedFirst seen
Area Business Manager (ABM)USOct 19, 2026Oct 20, 2026
Director/Associate Director, PharmacometricsPARAMUS NJ HYBRID, Paramus, NJ, USSep 12, 2026Oct 11, 2026
Manager, Clinical ResearchPARAMUS NJ HYBRID, Paramus, NJ, USSep 6, 2026Oct 11, 2026
National Account Director LeadUS REMOTE, USSep 1, 2026Oct 11, 2026
Area Business Manager (ABM)US REMOTE, USAug 15, 2026Oct 11, 2026

See all 8 jobs

Timeline

  1. Trial start Phase 2: Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH) source ↗
  2. Trial start Phase 2: A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD) source ↗
  3. Trial start Phase 1/Phase 2: NS-050/NCNP-03 in Boys With DMD (Meteor50) source ↗
  4. Trial start Phase 2: NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD) source ↗
  5. Trial start Phase 2: Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With Polyangiitis source ↗
  6. Trial start Phase 2: Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis source ↗
  7. Trial start Phase 2: Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53) source ↗
  8. Trial start Phase 4: Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502) source ↗
  9. Trial start Phase 3: Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X) source ↗
  10. Trial start Phase 3: Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53) source ↗
  11. Trial start Phase 2: Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) source ↗
  12. Trial start Phase 2: Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD) source ↗
  13. Trial start Phase 1/Phase 2: Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF source ↗
  14. Trial start Phase 1: Study of NS-9 in Patients With Liver Metastases source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 15

RecordTitlePhaseStatusStartPrimary completion
NCT05996003NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)Phase 2Active, not recruitingFeb 22, 2024Feb 26, 2027 (estimated)
NCT06053814NS-050/NCNP-03 in Boys With DMD (Meteor50)Phase 1/Phase 2Active, not recruitingSep 18, 20242028-03 (estimated)
NCT06046222Trial of Efficacy and Safety of NS-229 Versus Placebo in Patients With Eosinophilic Granulomatosis With PolyangiitisPhase 2Active, not recruitingDec 20, 20232026-12 (estimated)
NCT07441200Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)Phase 2Not yet recruitingJul 1, 2026Aug 1, 2028 (estimated)
NCT07441278A Clinical Trial of NS-863 in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Phase 2Not yet recruitingJul 1, 2026Sep 14, 2028 (estimated)
NCT04854096Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With MyelofibrosisPhase 2TerminatedJan 31, 2023May 16, 2024 (actual)
NCT04060199Study to Assess the Efficacy and Safety of Viltolarsen in Ambulant Boys With DMD (RACER53)Phase 3CompletedApr 14, 2020Oct 19, 2023 (actual)
NCT04956289Study to Assess the Safety, Tolerability, and Efficacy of Viltolarsen in Ambulant and Non-Ambulant Boys With DMD (Galactic53)Phase 2CompletedJul 1, 2021Jun 20, 2023 (actual)
NCT04768062Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)Phase 3Unknown status (ClinicalTrials.gov)Apr 13, 20212025-10 (estimated)
NCT03167255Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)Phase 2CompletedJul 6, 2017Oct 20, 2021 (actual)
NCT04687020Long-term Use of Viltolarsen in Boys With Duchenne Muscular Dystrophy in Clinical Practice (VILT-502)Phase 4Active, not recruitingJun 10, 20212032-09 (estimated)
NCT01423851Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MFPhase 1/Phase 2Completed2011-06Apr 22, 2020 (actual)
NCT02740972Safety and Dose Finding Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)Phase 2Completed2016-122018-03 (actual)
NCT04337112The Expanded Access Use of Viltolarsen in Duchenne Muscular Dystrophy With Confirmed Exon 53 Amenable MutationNot listedApproved for marketingNot listedNot listed
NCT00094003Study of NS-9 in Patients With Liver MetastasesPhase 1Completed2002-09Not listed

Open jobs 8

TitleLocation (from posting, not HQ)Employer postedFirst seenLevel
Area Business Manager (ABM)USOct 19, 2026Oct 20, 2026Not stated
Director/Associate Director, PharmacometricsPARAMUS NJ HYBRID, Paramus, NJ, USSep 12, 2026Oct 11, 2026Senior
Manager, Clinical ResearchPARAMUS NJ HYBRID, Paramus, NJ, USSep 6, 2026Oct 11, 2026Mid
National Account Director LeadUS REMOTE, USSep 1, 2026Oct 11, 2026Senior
Area Business Manager (ABM)US REMOTE, USAug 15, 2026Oct 11, 2026Senior
Associate Director, Clinical ResearchPARAMUS NJ HYBRID, Paramus, NJ, USJul 28, 2026Oct 11, 2026Senior
Director, Clinical ResearchParamus, NJ, USJun 12, 2026Oct 11, 2026Senior
Director, Translational MedicineParamus, NJ, USApr 29, 2026Oct 11, 2026Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Connect

See your connections at NS Pharma on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-18

Feedback